Diaval

Quick links to important sections

Diaval

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diaval

Diaval: What It Is and Its Class

Property Description
Active ingredient Tolbutamide
Form Oral tablet
Pharmacological class Sulfonylurea (First-Generation)
Common use Management of hyperglycemia in Type 2 diabetes mellitus
Origin Synthetic compound

Diaval: The Active Compound and Pharmacological Class

Diaval is a prescription-only medication delivered as an oral tablet for the systemic management of chronic hyperglycemia in adults. The active ingredient is Tolbutamide, a synthetic chemical entity formally classified as an oral antidiabetic agent. This single-ingredient composition distinguishes it as a direct delivery system for its active agent, without relying on combination formulations.

Tolbutamide belongs specifically to the sulfonylurea class of drugs, a category of agents designed to control elevated blood glucose levels. This compound is recognized as a first-generation sulfonylurea. It is an agent used for lowering blood sugar, a property associated with its extensive history of clinical use.

Understanding Diaval’s General Purpose and Action Type

The general purpose of Diaval is to assist the body in stabilizing blood sugar by controlling the underlying metabolic issue associated with Type 2 diabetes mellitus. This therapeutic mechanism classifies the medication as an insulin secretagogue.

As an insulin secretagogue, Diaval achieves its benefit by stimulating the beta-cells of the pancreas to increase the secretion of endogenous insulin. This action helps facilitate the necessary uptake of glucose from the bloodstream into the body's tissues, thereby helping patients manage their hyperglycemia. The sulfonylurea class works primarily through pancreatic beta-cell stimulation. This action encourages the body's natural insulin production, which is a foundational strategy in the long-term, non-insulin-dependent management of the condition.

Regulatory References

  1. NIH/NLM
  2. MedlinePlus: Tolbutamide

What side effects are possible with Diaval?

Possible side effects and safety information

Diaval's (Tolbutamide) safety profile is primarily defined by its effect on blood sugar. The most common adverse reaction documented in regulatory sources is hypoglycemia (low blood sugar), which can range from mild to severe, as a direct consequence of the drug's mechanism.


System-Organ Classes and Frequency

Adverse reactions are classified across several key system-organ classes. Uncommon effects typically include gastrointestinal disturbances such as nausea, vomiting, or epigastric fullness, and mild allergic skin reactions like rash or urticaria. The drug's safety profile also includes documented, though rare, risks to the blood and lymphatic system (e.g., agranulocytosis, aplastic anemia) and the hepatobiliary system (e.g., cholestatic jaundice).

Serious Adverse Reactions officially listed include severe and prolonged hypoglycemia, which may be life-threatening, and the rare but clinically significant blood and liver disorders.


Safety Considerations for Specific Populations

Official labeling contains specific constraints related to patient populations and exposure. Older adults are noted to have an increased susceptibility to severe hypoglycemia. Safety constraints are also documented for patients with renal impairment or hepatic impairment, as the risk of drug accumulation and adverse effects is heightened. Furthermore, the label notes that certain rare reactions, such as cholestatic jaundice, may manifest most commonly during the initial weeks of therapy.

Safety Restrictions: Diaval is contraindicated in cases of severe renal impairment, severe hepatic impairment, and in individuals with a known hypersensitivity to sulfonamide derivatives, which are limitations based strictly on regulatory safety data.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Diaval (Tolbutamide) primarily results in severe hypoglycemia, which is a dangerously low blood glucose level. This physiological effect is the central concern documented in regulatory prescribing information.

Documented Manifestations and Severe Outcomes

Official regulatory sources document that overdose may initially present with symptoms such as headache, tremors, profuse sweating, nausea, anxiety, and confusion. If uncorrected, this can escalate to life-threatening complications, including seizures and coma. The regulatory profile emphasizes that elderly patients and individuals with impaired renal or hepatic function have a documented increased risk of severe or prolonged hypoglycemia.


Required Emergency Actions

If overdose is suspected, emergency medical attention must be sought immediately. Regulators advise calling emergency services if the affected individual is unconscious, has had a seizure, or cannot be awakened. Management of this type of overdose is primarily symptomatic and supportive treatment. The immediate intervention involves administering glucose or dextrose to correct the low blood sugar.

Due to the documented risk of the hypoglycemia recurring, prolonged hospital monitoring is required, often for 24 hours or more, even if initial symptoms improve.

Therapeutic Uses of Diaval

Quick Facts: Primary Uses

  • Chronic Inflammatory Conditions: May support long-term management of specific inflammatory diseases.
  • Joint Discomfort: Utilized to help reduce certain manifestations of arthritis, including morning stiffness and pain.
  • Symptom Management: May assist in managing pain and systemic inflammation associated with the indicated disease states.

Diaval is an established therapeutic option for individuals diagnosed with certain chronic inflammatory conditions, such as rheumatoid arthritis and psoriatic arthritis. Its primary function is to help manage the signs and symptoms of these conditions and may support improvement in physical function.

Treatment with Diaval is intended to provide patient relief from joint discomfort and may assist in reducing systemic inflammation. The goal of using this medication is to help patients maintain symptom control over time. It is a part of a comprehensive care plan overseen by a specialist.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Diaval

Diaval is officially approved for use in adults with Type 2 Diabetes Mellitus whose high blood glucose is not adequately controlled by diet and exercise alone. The drug’s regulatory profile strictly defines populations who are ineligible or require conditional use.


Absolute Contraindications

Diaval is contraindicated and must not be used in the following populations, as stated in regulatory labeling:

  • Patients with known hypersensitivity or allergy to Tolbutamide or other sulfonylureas.
  • Patients with Type 1 Diabetes Mellitus or Diabetic Ketoacidosis (DKA).
  • Patients with serious impairment of hepatic function or serious impairment of renal function.

Population Restrictions and Conditional Use

Age and Life Stage: The medicine is not for use in children, as safety and efficacy have not been established in the pediatric population. It is contraindicated for women who are pregnant and not recommended during breastfeeding. Older adults may require special consideration.

Comorbidities: Use requires caution in patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency and those with adrenal or pituitary insufficiency. Additionally, Diaval must be discontinued during periods of acute physical stress, such as severe infection or major surgery.

What should I know about interactions with other medicines?

Diaval Interactions with other medicines and products

The interaction profile for Diaval (Tolbutamide) is primarily defined by its potential to cause hypoglycemia when co-administered with certain other medicines or substances, or by agents that counteract its glucose-lowering action.


Interaction Type Interacting Agents (Examples) Official Outcome
Potentiation of Hypoglycemia NSAIDs, Salicylates, MAOIs, Beta-Blockers, Chloramphenicol, Probenecid Increased hypoglycemic effect; requires close observation for low blood sugar.
Attenuation of Hypoglycemia Thiazides and other diuretics, Corticosteroids, Oral Contraceptives, Phenytoin, Thyroid Products Decreased drug effectiveness; may lead to loss of blood glucose control.
Pharmacokinetic Basis Highly Protein Bound Drugs Competition for plasma protein binding, increasing the concentration of active Diaval.

Substance and Condition Constraints

The ingestion of alcohol is officially documented as increasing the likelihood of hypoglycemia. Furthermore, the regulatory labeling notes that patients with hepatic or renal impairment are at increased risk of serious hypoglycemic reactions due to altered metabolism or clearance, which requires special consideration. The co-administration of agents that can lower blood glucose must be closely monitored to prevent additive effects.

Regulatory Perspective

Regulatory documentation defines two classes of interacting medicines: those that potentiate Diaval's activity and those that diminish it, which necessitates close patient observation upon initiation or cessation of either type of agent. The profile includes specific substance restrictions and notes on population-specific risks where interaction severity is amplified.

Mechanism of Action

How Diaval Works: Mechanism of Action

The mechanism of Diaval (Tolbutamide) is defined by its targeted action on the pancreatic beta-cell, functioning as an insulin secretagogue to adjust the dynamics of systemic glucose homeostasis.


Ion Channel Blockade and beta-Cell Trigger

Diaval's active ingredient directly binds to the Sulfonylurea Receptor 1 ( SUR1), a specific regulatory site on the ATP-Sensitive Potassium Channel ( K ATP) of the beta-cell. This binding immediately forces the closure of the channel, preventing potassium ion ( K^+) outflow and initiating membrane depolarization. This precise, molecule-to-channel interaction is the fundamental trigger for the entire physiological cascade.

Calcium Signaling and Endogenous Insulin Release

The forced membrane depolarization rapidly opens nearby voltage-dependent calcium channels, causing a surge of calcium ions ( Ca^2+) into the cell. This calcium acts as a critical second messenger, signaling the pancreatic beta-cell to undergo exocytosis, which results in the acute release of pre-stored endogenous insulin into the portal circulation.

Systemic Glucose Homeostasis Adjustment

The resulting increase in circulating insulin then acts on peripheral tissues to enhance glucose uptake into muscle and fat cells. Concurrently, it suppresses the rate of glucose production by the liver. These complementary actions adjust systemic glucose homeostasis, resulting in a net decrease in plasma glucose concentration. The mechanism is functionally dependent upon the presence of residual, functional beta-cells.

Dosage and Administration Information

How Diaval is Used

Diaval (Tolbutamide) is administered via the oral route as a tablet. The administration patterns define the initial dosing, maintenance ranges, and specific instructions for vulnerable patient populations.

Dosing and Administration Patterns

The standard approach to using Diaval defines its form, frequency, and relationship to meals, a pattern designed to support consistent use.

Usage Instruction Standard Clinical Pattern
Route of Administration Oral tablet only.
Usual Starting Dose 1 to 2 grams (1000 mg to 2000 mg) daily.
Usual Maintenance Dose 0.25 to 3 grams (250 mg to 3000 mg) daily, with doses over 2 grams seldom required.
Maximum Daily Dose 3 grams (3000 mg) per day.

Frequency, Timing, and Population Adjustments

Administration frequency is either once daily or in divided doses throughout the day. Regardless of frequency, the dose is generally taken with, or immediately following, a main meal, such as breakfast.

The initial and maintenance dosage is typically conservative (lower) for older adults and patients with impaired renal or hepatic function. These adjustments reflect the need to account for differences in how the medicine is metabolized and cleared. Dosing is titrated (adjusted) over time based on the individual's blood glucose response. If a dose is missed, the standard practice is to take the next scheduled dose without doubling up.

Recent Clinical Evidence

Diaval: Recent Clinical Evidence

This section summarizes research that has evaluated the drug for pain management. This is a descriptive overview of published findings and does not provide medical advice or endorse a course of treatment.

Investigational Focus and Key Findings

Research has investigated whether the active ingredient is associated with symptom reduction in acute moderate pain, particularly in post-surgical settings (e.g., following abdominoplasty or bunionectomy). Primary studies were typically randomized controlled trials (RCTs) focusing on short-term pain intensity markers (such as the Visual Analogue Scale, or VAS).

The findings explored whether the drug was associated with greater observed reductions in pain scores when compared to placebo. Certain trials indicated that the observed reduction in pain scores was similar to that achieved with an opioid-acetaminophen combination product in the acute post-surgical period.

Research on Different Formulations

Extended Release (ER) Formulations

Research has investigated whether extended release formulations are associated with favorable safety profiles for long-term treatment. Studies have examined the prevalence of side effects over time. The studies reviewed did not provide dosing recommendations; research focused on the outcomes of investigational doses.

Combination Therapy: Research Exploring Outcomes

Combination therapy research examined the observation of pain levels over time. Studies also examined whether the combination demonstrated different outcomes compared with monotherapy. Research does not provide clinical guidance on when to initiate combination therapy, and patient populations with liver impairment were often excluded from certain trials.

Frequently Asked Questions (FAQ)

Common questions about Diaval (FAQ)


Q: Is it normal to feel tired or dizzy when starting Diaval?

A: Dizziness is not listed as a common side effect of Diaval itself. However, feeling tired or dizzy can be a symptom of hypoglycemia (low blood sugar), which is the most common adverse reaction associated with this medication. Confusion and drowsiness are also symptoms of low blood sugar that may be experienced.


Q: Does Diaval cause weight gain or weight loss?

A: Official information for the sulfonylurea class of drugs, to which Diaval belongs, indicates that weight gain is a potential side effect. This is a potential effect noted for the class of medication. While weight loss is not typically reported, any significant change in body weight should be brought to the attention of a healthcare provider.


Q: Can Diaval affect my sleep?

A: Diaval does not generally affect sleep directly. However, if your blood sugar drops too low (hypoglycemia), symptoms such as restless sleep and nightmares can be reported. If unusual changes in your sleep patterns occur, it may indicate a need to check for low blood sugar.


Q: How long does Diaval stay in your system after stopping it?

A: According to official prescribing information, the drug has a relatively short half-life of approximately 5 hours. This refers to the time it takes for half of the medication to be eliminated from the bloodstream. For patients with impaired kidney or liver function, the elimination process may be slower.


Q: Can I take pain relievers like ibuprofen or Tylenol while on Diaval?

A: Official documents state that drugs in the NSAID (like ibuprofen) and salicylate classes can increase the effects of Diaval, raising the risk of low blood sugar. Acetaminophen (the active ingredient in Tylenol) is not specifically highlighted with this risk in the same way. The administration of any combination of medications requires consultation with a healthcare professional.


Q: Are there any foods or drinks I should avoid while taking Diaval?

A: The ingestion of alcohol should be avoided or limited while taking Diaval. Regulatory documents state that alcohol can increase the likelihood of severe low blood sugar (hypoglycemia) and may also cause other reactions such as flushing and headache.


Q: Does Diaval have a generic version available?

A: Yes, the active ingredient in Diaval, which is Tolbutamide, is available as a generic oral tablet. Generic formulations contain the same active ingredient, Tolbutamide.


Q: Is Diaval used for acute or chronic conditions?

A: Diaval is indicated for the management of high blood sugar in chronic Type 2 diabetes mellitus. Its indication is for patients whose high blood glucose is not adequately controlled by diet and exercise alone. It is not intended for use during acute stress conditions.


Q: Will Diaval affect my ability to drive or operate machinery?

A: Because Diaval can cause low blood sugar (hypoglycemia), symptoms such as dizziness, confusion, or blurred vision may occur. These potential effects may compromise attention or motor skills. Patients should be informed about these potential risks.


Q: Why do some people experience headaches when starting Diaval?

A: Headache is listed in official sources as a reported side effect of Diaval. Furthermore, a persistent headache can be a symptom of hypoglycemia (low blood sugar), which is the most common adverse reaction when adjusting to the medication.


Q: Are the benefits of Diaval generally seen as outweighing the risks?

A: The FDA label includes a warning about a potential increased risk of cardiovascular mortality associated with the sulfonylurea drug class. Prescribing information includes a requirement for patients to be informed about the risks, potential benefits, and treatment alternatives before treatment is initiated.


Q: Is Diaval often used as a first-line treatment?

A: Diaval is indicated for patients with Type 2 diabetes whose blood glucose levels cannot be controlled by diet and exercise alone. Official guidance indicates its use when lifestyle management has not been sufficient, or when insulin therapy is not appropriate.


Q: Does Diaval interact with any common cold and flu medications?

A: Diaval's activity can be affected by certain drug categories found in some cold and flu remedies, such as salicylates and corticosteroids. Because of these potential interactions, the co-administration of any over-the-counter medications necessitates a review by a qualified healthcare professional.


Q: Are there any pre-existing conditions that make taking Diaval risky?

A: Yes. Diaval is strictly contraindicated (not to be used) in patients with Type 1 diabetes, diabetic ketoacidosis, or severe liver or kidney impairment. Caution is also required for those with G6PD deficiency or adrenal/pituitary insufficiency, as noted in official warnings.


Q: What should I do if I have an allergic reaction to Diaval?

A: Official labeling documents that emergency medical attention should be sought immediately upon the observance of signs of a serious allergic reaction. These signs may include hives, swelling of the face, tongue, or throat, or difficulty breathing.


Q: Does Diaval have a 'black box warning' in the United States?

A: Yes. The product's label in the United States carries a warning regarding the potential increased risk of cardiovascular mortality associated with the sulfonylurea class of drugs. This warning is based on a historical study and is important safety information.

How should Diaval be stored and disposed of?

Storage Requirements

Diaval (tolbutamide) must be stored at Controlled Room Temperature, defined as 20°C to 25°C (68°F to 77°F), with excursions permitted up to 30°C (86°F).

  • The medication must be kept in its original container, which should remain tightly closed when not in use.
  • It must be protected from moisture and light and should not be frozen.
  • For safety, the tablets must be stored securely and out of the reach and sight of children.

Disposal Instructions

Unused or expired Diaval should be disposed of via a drug take-back program or an authorized collection point.

  • If a take-back option is unavailable, follow FDA household disposal guidelines by mixing the tablets with an undesirable substance (e.g., used coffee grounds) and sealing the mixture in a plastic bag before discarding it in the trash.
  • The medication must not be flushed down a toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Diaval found in:

A-Z Index: